HistoSonics has raised $4.8 million in a new debt and warrants round of financing, according to a recently posted SEC filing.
HistoSonics is developing an image-guided, robotically assisted platform therapy using non-invasive and non-thermal technologies, according to the company’s website.
Money in the round came from 20 anonymous investors, with the first sale noted on April 18.
The Ann Arbor, Michigan-based company is looking for an additional $175,000 before closing the round, with a minimum investment of $50,000 required, according to the filing.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.